InspireMD launches CGuard Prime in U.S. after FDA approval; revenue up 28% but loss widens 52%
Filed March 18, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 12, 2025 · ~2 min read
5 material changes detected in this filing.
Create a free account to read the full summary — it takes 30 seconds.
Partner
Trade NSPR commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · Jun 4, 2026 9:21 PM